Karamedica, Inc., a start-up biomedical company, recently received a Small Business Innovative Research (SBIR) grant from the National Institute of Aging to develop a microparticle therapy for cerebral amyloid angiopathy (CAA).
Karamedica’s therapy for CAA consists of “smart” microparticles that are made of a material called chitosan that is derived from chitin, a biopolymer found in the shells of shrimps, crabs, and other crustaceans. The aims of the project are to optimize plasma decontamination processes for chitosan microparticles, demonstrate the efficacy of “smart” chitosan microparticles in targeting cells in the blood vessels of the brain and preventing attack of these cells by the body’s immune system. Karamedica’s chitosan microparticles will prevent injuries to the cells of the brain’s blood vessels by triggering them to begin producing a natural inhibitor of the damaging products formed by the immune system.
Read more >>
Source: GlobeNewswire | October 10, 2018